Literature DB >> 15014539

Association between vascular dysfunction and reduced myocardial flow reserve in patients with hypertension: a LIFE substudy.

M H Olsen1, K Wachtell, C Meyer, J D Hove, V Palmieri, H Dige-Petersen, J Rokkedal, B Hesse, H Ibsen.   

Abstract

Impaired myocardial flow reserve (MFR) has been demonstrated in hypertension, and has been associated with peripheral vascular changes. We investigated whether MFR was impaired and associated with structural and/or functional vascular changes in hypertensive patients without evidence of coronary artery disease (CAD). We measured left ventricular (LV) mass index by echocardiography and MFR by positron emission tomography in 33 unmedicated, hypertensive patients with electrocardiographic LV hypertrophy without CAD, and 15 age- and gender-matched normotensive subjects. We also measured 24-h ambulatory blood pressure, minimal forearm vascular resistance (MFVR) by plethysmography, media:lumen ratio in isolated, subcutaneous resistance arteries by myography, intima-media cross-sectional area of the common carotid artery, and flow-mediated (FMD) and nitroglycerin-induced dilatation (NID) of the brachial artery by ultrasound. Compared to the controls, the patients had impaired MFR (2.4 (95% CI 1.95-2.8) vs 3.4 (2.7-4.2), P<0.01) due to increased resting myocardial blood flow (MBF) (0.82 (0.73-0.91) vs 0.65 (0.56-0.75) ml/g min), and decreased dipyridamole-stimulated MBF (1.80 (1.55-2.1) vs 2.3 (1.80-2.8) ml/g min, both P<0.05). The difference in resting MBF disappeared (80 (74-87) vs 86 (74-97) microl/kg mmHg, NS) when normalized for blood pressure and heart rate. MFR correlated negatively to median 24-h systolic blood pressure (r=-0.50, P<0.01) as well as to LV mass index (r=-0.45, P<0.05) and MFVR in men (r=-0.47, P<0.05), and positively to FMD (r=0.44, P<0.05) and NID (r=0.40, P<0.05). Hypertensive patients with electrocardiographic LV hypertrophy without CAD had impaired MFR associated with cardiovascular hypertrophy and vasodilatory dysfunction. This suggests that MFR is impaired by LV hypertrophy and structural/functional vascular damage in the coronary and noncoronary circulation.

Entities:  

Mesh:

Year:  2004        PMID: 15014539     DOI: 10.1038/sj.jhh.1001716

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  7 in total

Review 1.  Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy.

Authors:  Chike C Nwabuo; Ramachandran S Vasan
Journal:  Curr Hypertens Rep       Date:  2020-02-03       Impact factor: 5.369

Review 2.  Endothelial dysfunction: its role in hypertensive coronary disease.

Authors:  Islam Bolad; Patrice Delafontaine
Journal:  Curr Opin Cardiol       Date:  2005-07       Impact factor: 2.161

Review 3.  Non-invasive Risk Stratification for Coronary Artery Disease: Is It Time for Subclassifications?

Authors:  Pupalan Iyngkaran; Samer Noaman; William Chan; Gnanadevan Mahadavan; Merlin C Thomas; Sharmalar Rajendran
Journal:  Curr Cardiol Rep       Date:  2019-07-25       Impact factor: 2.931

4.  β2-adrenergic stress evaluation of coronary endothelial-dependent vasodilator function in mice using (11)C-acetate micro-PET imaging of myocardial blood flow and oxidative metabolism.

Authors:  Etienne Croteau; Jennifer M Renaud; Christine Archer; Ran Klein; Jean N DaSilva; Terrence D Ruddy; Rob Sb Beanlands; Robert A deKemp
Journal:  EJNMMI Res       Date:  2014-12-16       Impact factor: 3.138

Review 5.  Coronary blood flow in heart failure: cause, consequence and bystander.

Authors:  Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2022-01-13       Impact factor: 12.416

Review 6.  Positron emission tomography for quantitation of myocardial perfusion.

Authors:  Ornella E Rimoldi; Paolo G Camici
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

Review 7.  Quantitative cardiac positron emission tomography: the time is coming!

Authors:  Roberto Sciagrà
Journal:  Scientifica (Cairo)       Date:  2012-08-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.